4.09
-0.73%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Thor Medical A
Its shares trade on Oslo Børs under the ticker TRMED.OL. It has been listed since 7 July 2014. In the fiscal year to 31 December 2025, it reported revenue of NOK 439,000 and a net loss of NOK 58.0m. At that date it held total assets of NOK 708.6m and shareholders' equity of NOK 456.0m.
Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo. The company went IPO on 2014-07-07. The company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). The company is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. The company has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Jul 2014
- Employees
- 37
- Website
- nordicnanovector.com ↗
Leadership
Pay as last reported
- Mr. Ludvik SandnesIndependent Chairman of the Board, since 2013NOK 350,000
- Mr. Jasper KurthChief Executive OfficerNOK 2.0m
- Mr. Brede EllingsaeterChief Financial and Operating OfficerNOK 2.4m
- Dr. Alf BjornsethExecutive Vice President - Business DevelopmentNOK 1.8m
- Dr. Sindre HassfjellChief Technology OfficerNOK 2.8m
- Ms. Astrid LilandVice President - HSEQNOK 2.4m
- Mr. John AndersenDirectorNOK 350,000
- Ms. Mimi BerdalIndependent DirectorNOK 350,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 36
- Social
- 51
- Governance
- 18
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nordic Nanovector ASA possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong portfolio of innovative products and technologies in the field of targeted therapeutics for cancer treatment. This allows Nordic Nanovector ASA to differentiate itself from competitors and attract potential customers.
- Secondly, the company has a highly skilled and experienced team of researchers, scientists, and professionals who contribute to the development and advancement of its product pipeline. This expertise enables Nordic Nanovector ASA to maintain a high level of quality and efficiency in its research and development processes.
- Lastly, Nordic Nanovector ASA enjoys a solid financial position, with sufficient capital reserves to fund its operations and strategic initiatives. This financial stability provides the company with a competitive edge and enables it to invest in growth opportunities and expand its market presence.
Weaknesses
- However, Nordic Nanovector ASA also faces certain weaknesses that may hinder its growth and competitive position. One major weakness is the company's heavy reliance on a limited number of product candidates. If any of these candidates fail to meet regulatory or clinical trial requirements, it may significantly impact the company's revenue stream and overall performance.
- In addition, Nordic Nanovector ASA currently lacks a diversified product portfolio, which makes the company more vulnerable to market fluctuations and changes in customer preferences. The absence of alternative revenue streams puts the company at risk of relying too heavily on the success of a few key products.
Opportunities
- Despite its weaknesses, Nordic Nanovector ASA has several opportunities to capitalize on and enhance its market position. Firstly, the increasing prevalence of cancer globally presents a significant opportunity for the company to address unmet medical needs and expand its customer base.
- Furthermore, partnerships and collaborations with other pharmaceutical companies or research institutions provide Nordic Nanovector ASA with opportunities to access additional resources, knowledge, and expertise. Such collaborations can accelerate the development and commercialization of the company's products, ultimately strengthening its competitive advantage.
Threats
- Nordic Nanovector ASA also faces certain threats that could potentially impact its performance and market position. One significant threat is the intense competition within the pharmaceutical industry. The presence of established competitors with similar products and technologies may limit the company's market share and profitability.
- Another threat is the stringent regulatory requirements and approval processes imposed by regulatory authorities. Any delays or failures in obtaining necessary approvals can significantly impede the company's ability to bring its products to market in a timely manner and generate revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.